206 related articles for article (PubMed ID: 29480845)
1. Association of rs2279744 and rs117039649 promoter polymorphism with the risk of gynecological cancer: A meta-analysis of case-control studies.
Zhang J; Zhang Y; Zhang Z
Medicine (Baltimore); 2018 Jan; 97(2):e9554. PubMed ID: 29480845
[TBL] [Abstract][Full Text] [Related]
2. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
[TBL] [Abstract][Full Text] [Related]
3. MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis.
Peng Q; Mo C; Qin A; Lao X; Chen Z; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
J Exp Clin Cancer Res; 2013 Nov; 32(1):85. PubMed ID: 24423195
[TBL] [Abstract][Full Text] [Related]
4. MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis.
Wang LH; Wang X; Xu WT; Hu YL
Tumour Biol; 2014 Apr; 35(4):3167-70. PubMed ID: 24293392
[TBL] [Abstract][Full Text] [Related]
5. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
Gansmo LB; Bjørnslett M; Halle MK; Salvesen HB; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
BMC Cancer; 2017 Feb; 17(1):97. PubMed ID: 28158999
[TBL] [Abstract][Full Text] [Related]
6. Association of the
Miedl H; Lebhard J; Ehart L; Schreiber M
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691044
[TBL] [Abstract][Full Text] [Related]
7. Association between MDM2 SNP309 and endometrial cancer risk: A PRISMA-compliant meta-analysis.
Zou X; Zhang Y; Zhang L; Li J; Zhu C; Cheng Q; Zhou J; Chen Y
Medicine (Baltimore); 2018 Dec; 97(49):e13273. PubMed ID: 30544386
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis.
Economopoulos KP; Sergentanis TN
Breast Cancer Res Treat; 2010 Feb; 120(1):211-6. PubMed ID: 19590949
[TBL] [Abstract][Full Text] [Related]
9. The association between murine double minute 2 (MDM2) rs2279744 and endometrial cancer risk in a Chinese Han population.
Wu JP; Luo X
Cell Mol Biol (Noisy-le-grand); 2017 Oct; 63(10):128-130. PubMed ID: 29096752
[TBL] [Abstract][Full Text] [Related]
10. [Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].
Wang ML; Xu YX; Qian J; Wang FH
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):124-8. PubMed ID: 23719102
[TBL] [Abstract][Full Text] [Related]
11. Relationship Between Murine Double Minute 2 (MDM2) T309G Polymorphism and Endometrial Cancer Risk: A Meta-Analysis.
Xue Z; Zhu X; Teng Y
Med Sci Monit; 2016 Sep; 22():3186-90. PubMed ID: 27604213
[TBL] [Abstract][Full Text] [Related]
12. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma.
Singhal P; Hussain S; Thakur N; Batra S; Salhan S; Bhambani S; Bharadwaj M
DNA Cell Biol; 2013 Jan; 32(1):19-27. PubMed ID: 23210739
[TBL] [Abstract][Full Text] [Related]
13. Common variant on MDM2 contributes to endometrial cancer susceptibility: evidence based on 7 studies.
Zhao Y; Yang X; Hao X; Pan X; Zhao B; Ma J; Fang J; Zhao M
Tumour Biol; 2014 Aug; 35(8):7555-60. PubMed ID: 24792886
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
Li Y; Zhao H; Sun L; Huang L; Yang Q; Kong B
Hum Cell; 2011 Jun; 24(2):57-64. PubMed ID: 21547352
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies.
Elshazli RM; Toraih EA; Elgaml A; Kandil E; Fawzy MS
Gene; 2020 Apr; 734():144391. PubMed ID: 32001373
[TBL] [Abstract][Full Text] [Related]
16. Role of CYP1A2 1F polymorphism in cancer risk: evidence from a meta-analysis of 46 case-control studies.
Tian Z; Li YL; Zhao L; Zhang CL
Gene; 2013 Jul; 524(2):168-74. PubMed ID: 23628800
[TBL] [Abstract][Full Text] [Related]
17. CYP1A1 polymorphism and risk of gynecological malignancy in Japan.
Sugawara T; Nomura E; Sagawa T; Sakuragi N; Fujimoto S
Int J Gynecol Cancer; 2003; 13(6):785-90. PubMed ID: 14675315
[TBL] [Abstract][Full Text] [Related]
18. Murine double minute clone 2,309T/G and 285G/C promoter single nucleotide polymorphism as a risk factor for breast cancer: a Polish experience.
Piotrowski P; Lianeri M; Rubis B; Knuła H; Rybczyńska M; Grodecka-Gazdecka S; Jagodziński PP
Int J Biol Markers; 2012 Jul; 27(2):e105-10. PubMed ID: 22467100
[TBL] [Abstract][Full Text] [Related]
19. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
20. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
Knappskog S; Trovik J; Marcickiewicz J; Tingulstad S; Staff AC; ; Romundstad P; Hveem K; Vatten L; Salvesen HB; Lønning PE
Eur J Cancer; 2012 Sep; 48(13):1988-96. PubMed ID: 22119201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
